Why the study?
Does Transcatheter Aortic Valve Replacement (TAVR) improve health status in an unselected population?
Does Transcatheter Aortic Valve Replacement (TAVR) improve health status in an unselected population?
In a real-world national cohort, TAVR improved health status similarly to pivotal trials, though 1 in 3 patients still had poor outcomes at 1 year.
Answers are grounded in this paper and cite their sources.
Extends TAVR health status gains to unselected real-world patients; leaves open prediction of poor 1-year outcomes.
In a national, contemporary clinical practice cohort of unselected patients, improvement in health status after TAVR was similar to that seen in the pivotal clinical trials. Although the health status results were favorable for most patients, approximately 1 in 3 still had a poor outcome 1 year after TAVR. Continued efforts are needed to improve patient selection and procedural/postprocedural care to maximize health status outcomes of this evolving therapy.
No takes yet. Share an insight, caveat, or question.
Arnold et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: